Relibeta Injection
Interferon Beta 1a
Reliance Formulation Pvt Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Relibeta Injection is used for:
Multiple Sclerosis
Adult Dose
Parenteral
Multiple sclerosis
Adult: Dose depends on the formulation used.
Intramuscular
30 mcg IM qWk
May be titrated using the titration kit with prefilled IM syringes starting with 7.5 mcg IM for first week, to reduce flu-like symptoms; increase by 7.5 mcg/week for next 3 weeks until recommended dose of 30 mcg/week
Administration: Rotate IM injection sites between upper thighs and arms
Subcutaneous
44 mcg target dose
Weeks 1-2: 8.8 mcg SC 3 times/wk (at least 48 hr apart)
Weeks 3-4: 22 mcg SC 3 times/wk
Weeks 5+: 44 mcg SC 3 times/wk
22 mcg target dose
Weeks 1-2: 4.4 mcg SC 3 times/wk (at least 48 hr apart)
Weeks 3-4: 11 mcg SC 3 times/wk
Weeks 5+: 22 mcg SC 3 times/wk
Administration: Abdomen (except waistline), thigh, arm, buttocks
Child Dose
Safety and efficacy not established
Renal Dose
Administration
Contra Indications
Hypersensitivity to beta interferons, albumin (for albumin-containing formulations)
Precautions
Caution when used in patients with depression or psychiatric disorders, epilepsy or other CNS diseases, poorly controlled thyroid dysfunction, pulmonary disease, DM, renal or hepatic impairment, cardiac disorders, myelosuppression, auto-immune diseases, coagulation disorders, or a history of these conditions. Monitor blood counts especially in patients at high risk of myelosuppression. Eye examination should be conducted prior to starting treatment and regularly thereafter. Monitor hepatic and renal function regularly. Treatment should be discontinued in patients with chronic hepatitis who develop liver decompensation. May affect ability to drive or operate machinery. Pregnancy.
Lactation: unknown; use caution
Pregnancy-Lactation
Interactions
May increase the adverse effects (especially granulocytopenia) of ACE inhibitors. Increased risk of hepatic injury when used with hepatotoxic drugs. May increase serum levels of theophylline derivatives. May increase the anticoagulant effects of warfarin. May decrease the metabolism of zidovudine.
Adverse Effects
Side effects of Interferon Beta 1a :
>10%
Injection site reactions (83% [SC]; 28% [IM],Headache (67%),Flu-like syndrome (61%),Muscle ache (34%),Nausea (33%),URT infection (14%),Pain (24%),Fever (23%),Asthenia (21%),Diarrhea (16%),Dizziness (15%),Infection (11%),Dyspepsia (11%)
1-10%
Abdominal pain (9%),Anemia (8%),Chest pain (6%)
<1%
Aggravation of seizure disorders
Mechanism of Action
Interferon beta 1a alters the expression and response to surface antigens and can improve immune cell activities. It has antiviral and immunomodulating properties.
Note
Relibeta Injection manufactured by Reliance Formulation Pvt Ltd.. Its generic name is Interferon Beta 1a. Relibeta is availble in Nepal.
Farmaco Nepal drug index information on Relibeta Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.